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of emotional support. CONCLUSIONS: This exploratory study
supports the construct validity of the SBDD measure because
SBDD was associated with SF-36 domains in expected ways.
SBDD was associated with certain predictors of future health
status, including health behaviors such as regular exercise. SBDD
could be use as a community indicator to assess the burden of
mental distress in women in Venezuela.
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OBJECTIVES: To assess health-related quality of life (QoL) of
married, working women with children (working-moms) faced
with psychosocial stress (known as superwoman syndrome).
METHODS: A total of 200 working-moms (aged 40.2  5.3)
were recruited randomly by telephone, and a questionnaire was
administered to classify types of superwomen syndrome: self-
reliance type (ST), conﬂict type (CT), and additive type (AT). To
compare, a community samples of aged group (n = 80, aged 70.0
 5.9) were recruited at a local community center. We measured
QoL using SF-36v2 for both groups. RESULTS: As expected
younger working-moms reported signiﬁcantly higher physical
function (PF: 79.7 18.7 vs. 71.9 21.9; p = .0031) and mental
health (MH: 49.2  15.3 vs. 41.0  14.8; p < .0001). On the
contrary role-physical (RP: 78.9  23.6 vs. 80.5  22.5) and
role-emotional (RE: 77.2  25.0 vs. 83.2  24.0) scores were
lower than aged. Additionally, social functioning (SF) was signiﬁ-
cantly lower in working-moms (p < .0003). Further by types, most
physical-related scales of ST group (n = 10) were signiﬁcantly
higher (all p’s < 0.0025), whereas vitality (VT) and MH were
lower than aged.Majority of working-momswere classiﬁed as CT
group (n = 169). They reported the same QoL patterns as total
samples. Notably, AT group (n = 21) reported only MH (62.9 
13.8 vs. 41.0  14.8; p < 0.0001) was signiﬁcantly higher than
aged, and rest were either similar (PF, VT), or signiﬁcantly lower
than aged (RP: 62.8  24.6 vs. 80.5  22.5, RE: 55.1  26.6 vs.
83.2  24.0; all p’s < 0.002). CONCLUSIONS: Most working-
moms reported higher functioning and well-being, but in fact they
were limited in playing roles due to physical andmental problems.
It is suspected that they are denying and suppressing their various
health problems. Particularly, additive group report they are in
well-being, but the study showed they are deﬁnitely not. They even
may develop mentally and physically-related diseases in the near
future. Therefore, a cohort study is urgent for working, married
women with children in Korea.
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OBJECTIVES: Develop a cross-cultural translation, Swedish to
Spanish, of TOOL questionnaire—a previously validated instru-
ment to assess the impact of adverse effects (AE) on the health
utilities and health related quality of life (HRQoL) in patients
with schizophrenia and bipolar disorder. METHODS: TOOL
questionnaire has 8 attributes and 4 levels per domain (Likert
scale). These domains are mood (anxiety and depression), func-
tion capabilities, and AE frequently associated with antipsy-
chotic drugs (fatigue-weakness, weight gain, stiffness-tremor,
physical restlessness, sexual dysfunction, and vertigo-nausea).
Firstly, 4 independent translators (3 Spanish and 1 Swedish)
carried out the forward-backward translations of the original
TOOL questionnaire. Next, draft version was reviewed by an
experts panel (5 psychiatrists & 1 GP specialized in HRQoL)
and tested in 40 stable patients (20 schizophrenic & 20
bipolar). Regarding patients’ responses, comprehension and
importance (C/I) of each item were evaluated by using a Likert
scale ranging from 0 (lowest level of C/I) to 4 (highest level of
C/I). Furthermore, feasibility and internal consistency were pre-
liminary analyzed. RESULTS: According to experts’ criteria 3
items should be modiﬁed to facilitate comprehension: mood,
physical restlessness and vertigo-nausea. However, C/I of items
mean scores were respectively: mood (3.50/2.37); function capa-
bilities (2.58/2.03); fatigue-weakness (3.58/2.55); weight gain-
(3.75/2.87); stiffness-tremor (3.65/2.61); restlessness (3.37/
2.62); sexual dysfunction (3.39/2.51) and vertigo-nausea (3.56/
2.44). Furthermore, only 2 patients (5%) were unable to
complete this questionnaire. Internal consistency was high
(Cronbach a = 0.87) and neither item ceiling nor ﬂoor effects
were found in patients responses. Finally, the Spanish version of
the TOOL questionnaire was reached by consensus. CONCLU-
SIONS: The Swedish TOOL questionaire was culturally
adapted into Spanish. Psychometric analyses are needed to vali-
date this HRQoL measure in Spain. Moreover, a multtiatribute
utility fuction should be estimated to evaluate AE by using a
patients’ centered perspective.
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OBJECTIVES: 1) To develop a linguistically validated version of
the DMI-18 in Castilian; 2) to evaluate its sensitivity and speci-
ﬁcity as a screening tool for depression in a sample of patients
with an organic illness attending the General Hospital of
Galdakao—Usansolo; and 3) to compare its screening qualities
with the ones of the most used screening tools, such as the
Hospital and Anxiety Depression Scale (HADS), the Beck
Depression Inventory Fast Screen (BDI-FS) and the Patient
Health Questionnaire-9 (PHQ-9). METHODS: The DMI-18 was
validated linguistically into Castilian using the translation—
backtranslation method recommended by Acquadro, Conway,
Giroudet, and Mear, (2004). Researchers interviewed somatic
patients (n = 11) and experts in depression (n = 3) to detect
possible understanding difﬁculties in the DMI-18 questions. Dr.
Parker, original author of the DMI-18, collaborated during the
translation process. The sample was composed by 156 outpa-
tients and inpatients that were attending some service of the
Hospital. Patients completed the DMI-18, HADS, BDI-FS and
the PHQ-9. Immediately afterwards a mental health clinician
interviewed patients individually using a psychiatric semistruc-
tured interview (PRIME-MD) to state whether the patient pre-
sented or not an affective disorder. The resulting diagnoses
coming from the self application of the screening tests were
compared against the clinical assessments made by the expert in
mental health. These data were used to calculate the sensitivity
and the speciﬁcity of the DMI-18, and of the competing screening
instruments. RESULTS: Using the clinicians valuation as the gold
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standard, and setting a cut-off scores of 20 for the DMI-18, >8
for the HADS, >5 for the PHQ-9, and >4 for the BDI-FS to
diagnose depression. CONCLUSIONS: The Spanish validated
DMI-18 scale maintains an adequate conceptual and semantic
equivalence with the original and is easily understood by
patients. It also has shown adequate sensitivity and speciﬁcity in
the detection of affective disorders with similar results to those of
the original version (sensitivity 91.7%–95.0%, speciﬁcity
68.1%–72.4%). Its sensitivity to detect depression is compara-
tively lower than the sensitivity of the convergent measures, but
its speciﬁcity if notably better.
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BACKGROUND: Patient centered care requires physicians to
accommodate views and needs of patients, but to date there has
been little evidence as to the degree of concordance between
patients and physicians in terms of their treatment goals and its
achievement. OBJECTIVES: To identify, value and compare the
treatment goals of patients and physicians for the treatment of
schizophrenia, and to measure self reported and physician per-
formance of patients with respect to these goals. METHODS: A
mixed methods approach was taken combining qualitative and
quantitative data. First, 20 relevant treatment goals were iden-
tiﬁed through patient focus groups (n = 30) and literature. A
survey was then developed to rank the goals and to rate its
importance using 5-point Likert scales. Finally degree of
achievement was assessed. The survey was administered to both
patients (n = 105) and physicians (n = 160) by trained ﬁeld
workers. Data was analyzed using means and t-tests as appro-
priate. RESULTS: We found that the three most important goals
for patients were: reduction of anxiety (80.5), improvement of
cognitive abilities (79.25), and reduced feelings of depression
(79). Physicians rated: reduction of symptoms (82.25), increase
of self-conﬁdence (80.75), and improvement of cognitive abili-
ties (80.5) as having the highest importance. When asked to rate
the performance of patients with respect to these goals, we
found that physicians continuously judged more critical than
patients. Signiﬁcant differences were found for improvement of
cognitive abilities (p < 0.05), increase of independence (p <
0.05), decrease lack of emotion (p < 0.05), increase of overall-
satisfaction (p < 0.05), improved ability to express oneself (p <
0.05), and recreation of social contacts (p < 0.05). CONCLU-
SIONS: Results suggest that schizophrenic patients and physi-
cians value treatment goals and their achievement relative
discordant. As schizophrenic patients are capable to state their
requirements, this should be considered in treatment decisions
to improve treatment outcomes.
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OBJECTIVES: While the clinical efﬁcacy of drugs for ADHD is
widely studied in clinical trials (usually randomised controlled
trials, RCTs), patient preferences with regard to their treatments
are not well understood and therefore considered to a less
extend. Aim of this study therefore was to explore the patients
perceptions of an “ideal treatment” for ADHD. METHODS:
Examination of the state of the art as reported in the literature
was followed by a qualitative study with four focus groups
consisting of 6–8 parents of ADHD-patients each. In a subse-
quent quantitative study phase, data was collected in an online or
paper-pencil self-ﬁll-in questionnaire for parents of patients and
patient (age >14 years) themselves. It included sociodemographic
data, treatment history and actual treatment and patients pref-
erences of therapy characteristics using direct measurement (23
items on a 5-point Likert-scale) as well as a discrete-choice-
experiment (DCE, 8 pairs with 6 characteristics). RESULTS: N =
213 questionnaires were ﬁlled; most of them by the parents of
patients (79% by the mothers, 9% by the fathers). Most of the
patients were male (83%) and most of them (83%) had actual
medical treatment of ADHD. Direct measurement showed “good
emotional quality of live”, “no addiction on medication”,
“improvement of concentration capability,” and “few side
effects” in the ﬁrst places. In the DCE, alternatives with “better
social quality of life (friendships etc. possible)”, “better emo-
tional quality of life (disease not all of the time mentally
present)”, and “longer duration of medication effect” were more
likely to be chosen, giving thus similar results. CONCLUSIONS:
N = 213 questionnaires were ﬁlled; most of them by the parents
of patients (79% by the mothers, 9% by the fathers). Most of the
patients were male (83%) and most of them (83%) had actual
medical treatment of ADHD. Direct measurement showed “good
emotional quality of live”, “no addiction on medication”,
“improvement of concentration capability,” and “few side
effects” in the ﬁrst places. In the DCE, alternatives with “better
social quality of life (friendships etc. possible)”, “better emo-
tional quality of life (disease not all of the time mentally
present)”, and “longer duration of medication effect” were more
likely to be chosen, giving thus similar results.
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OBJECTIVES: Traditionally, unmet needs are assessed using
claims data, clinician-reported metrics, or patient-reported
metrics from clinical trials. We seek to use patient-reported
survey data from ﬁve European countries to quantify unmet
needs of patients with depression currently using selective sero-
tonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine
reuptake inhibitors (SNRIs). This study will highlight the beneﬁts
of patient-reported survey data. METHODS: We analyzed data
from the 2007 European National Health and Wellness Survey,
an annual, cross-sectional, patient-reported survey of adults
(aged 18+) in France, Germany, Italy, Spain, and the UK. The
sample for analysis consisted of patients with diagnosed depres-
sion currently using an SSRI or SNRI and excluded patients with
bipolar disorder. Unmet needs were deﬁned as an afﬁrmative
response to the following symptoms in the past month: bothered
by feeling down, depressed or hopeless; and bothered by having
little interest or pleasure in doing things. Survey data were pro-
jected to national populations. Chi-square was used to test for
differences across countries. RESULTS: We found 1630 SSRI and
355 SNRI users in the sample, projecting to 6.93 and 1.46
million, respectively. There were 82.5% of SSRI users and 84.3%
of SNRI users who were bothered by feeling down, depressed, or
hopeless, equating to 5.71 and 1.23 million, respectively. Simi-
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